SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-021063
Filing Date
2023-06-13
Accepted
2023-06-13 16:10:25
Documents
13
Period of Report
2023-06-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 53231
2 ex99-1.htm EX-99.1 34100
  Complete submission text file 0001493152-23-021063.txt   267598

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE rspi-20230607.xsd EX-101.SCH 2962
4 XBRL LABEL FILE rspi-20230607_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE rspi-20230607_pre.xml EX-101.PRE 22361
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3332
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 231011330
SIC: 2834 Pharmaceutical Preparations